Summary: The US Food and Drug Administration (FDA) has found that marijuana has a lower potential for abuse compared to other drugs under the same restrictions, supporting its reclassification as a Schedule 3 drug. This reclassification would align marijuana with drugs that have a moderate to low potential for physical and psychological dependence.
Marijuana Reclassification To Schedule 3 Drug Supported by FDA Review
Marijuana, currently classified as a Schedule I substance, is considered among the most dangerous controlled substances, alongside heroin and LSD. However, recent FDA documents support its reclassification to Schedule III, which includes drugs like ketamine, testosterone, and Tylenol with codeine. This recommendation is based on three criteria: marijuana’s lower abuse potential compared to Schedule I and II substances, its accepted medical use in the US, and its low to moderate physical dependence risk.
The FDA’s evaluation indicates that despite the high prevalence of nonmedical marijuana use in the US, it does not lead to serious outcomes compared to drugs like heroin, oxycodone, and cocaine. This is noteworthy, especially considering the availability of high THC products. The FDA also acknowledges some scientific support for marijuana’s therapeutic uses, particularly for anorexia, pain, and chemotherapy-induced nausea and vomiting. However, they clarify that this does not imply established safety and effectiveness for any specific health condition.
Marijuana withdrawal, primarily observed in heavy, chronic users, is reportedly milder compared to alcohol withdrawal. The symptoms, similar to those from chronic use of Marinol and Syndros (FDA-approved synthetic THC products), align with tobacco withdrawal in terms of magnitude and timeline.
Rescheduling marijuana could facilitate research, ease banking for cannabis businesses, and exempt them from a tax code that currently disallows credits and deductions from income generated by Schedule I and II substances. Twenty-four states, two territories, and DC have legalized cannabis for adult recreational use, and 38 states allow medical cannabis.
The DEA will have the final say in any scheduling changes, following a rulemaking process that includes public comments before finalizing any action.
Why It Matters: The potential reclassification of marijuana as a Schedule 3 drug marks a significant shift in the federal government’s stance on cannabis. It reflects a growing recognition of marijuana’s medical benefits and lower abuse potential, potentially leading to more research opportunities and easing restrictions on cannabis businesses.
Potential Implications: If marijuana is reclassified, it could lead to broader acceptance and use of cannabis for medical purposes, stimulate further research into its therapeutic benefits, and significantly impact the legal and financial landscape of the cannabis industry.
We hope you enjoyed this news update. Check back with us daily to see what’s going on in the world of cannabis and psychedelics. And make sure to subscribe to our weekly newsletter, the Cannadelics Sunday Edition with a the best stories of the week:
.
.
AI Disclaimer: This news update was created using a AI tools. PsychePen is an AI author who is constantly improving. We appreciate your kindness and understanding as PsychePen continues to learn and develop.Please note that the provided information is derived from various sources and should not be considered as legal, financial, or medical advice.
The federal administration is all over the board around fed cannabis policy…and millions of patients are worried.
The industry employees over 440,000 workers at all lives and is driven in a large part by mom and pop businesses. Millions use medical marijuana for health issues ranging from chronic pain to sleep. But there are mixed messages from the feds about cannabis, and people are very worried. The federal government’s stance on marijuana has become increasingly complex, as recent developments show conflicting approaches to the drug’s potential benefits and risks. On one hand, there’s a push for research into medical marijuana for veterans, while on the other, a campaign against cannabis use is being launched.
The juxtaposition of initiatives highlights the federal government’s inconsistent approach to marijuana policy. While some departments are exploring the potential benefits of cannabis, others are actively working to discourage its use. This dichotomy is further exemplified by ongoing legislative efforts. For instance, Rep. Brian Mast (R-FL) has reintroduced the Veterans Equal Access Act, which would allow VA doctors to recommend medical marijuana to patients in states where it’s legal. Meanwhile, documents from an ongoing lawsuit suggest that the DEA may have weighted the marijuana rescheduling process to ensure rejection of moving the drug from Schedule 1 to Schedule 3.
Photo by yavdat/Getty Images
The Department of Defense (DOD) has allocated nearly $10 million in funding for research into the therapeutic potential of MDMA for active-duty military members. This initiative, driven by congressional efforts, aims to explore MDMA’s effectiveness in treating conditions such as post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Rep. Morgan Luttrell (R-TX) expressed pride in this development, stating that it could be a “game-changer” for service members battling these combat-related injuries.
Additionally, a bipartisan effort in Congress has been pushing for VA research on medical marijuana for PTSD and other conditions affecting veterans. The VA Medicinal Cannabis Research Act, introduced in both the Senate and House, would mandate studies on how cannabis affects the use of addictive medications and impacts various health outcomes for veterans.
In stark contrast to these research initiatives, the Drug Enforcement Administration (DEA) has partnered with an anti-cannabis nonprofit to launch a social media campaign targeting young people. The campaign, set to run ahead of April 20 (4/20), aims to “flood” Instagram with anti-cannabis content. The DEA is offering monetary incentives to students for creating and posting anti-THC videos, with payments ranging from $25 to $50 depending on the type of content produced.
This approach has raised eyebrows, as it seems to contradict the growing acceptance and legalization of marijuana across the United States. Critics argue that such campaigns may be out of touch with current societal trends and scientific understanding of cannabis.
Not everyone has access to marijuana to help them sleep – good news, hemp is available.
it’s estimated 50 to 70 million Canadian and American adults experience sleep disorders or disturbances, and about one-third of adults don’t regularly get the recommended amount. Hemp has emerged as a promising natural remedy for those seeking better sleep. With its calming properties and potential to address various sleep-related issues, hemp-derived products are gaining popularity among individuals looking to improve their rest. Here is how hemp helps you sleep.
Hemp contains several compounds contributing to better sleep quality. Cannabidiol (CBD), a non-psychoactive component of hemp, has shown potential in promoting relaxation and reducing anxiety, which can often interfere with a good night’s rest. Studies suggest that CBD may help individuals fall asleep faster and experience fewer sleep disturbances throughout the night.
When formulated and used properly, preliminary research and user reports suggest that hemp gummies improve subjective sleep quality. Users of quality hemp sleep gummies report feeling more rested, a better quality of sleep and fewer awakenings in the night. However, clinical research has shown that over consumption of THC negatively impacts the quality of sleep, especially with long term use.
Wana Brands has launched a hemp sleeping product nationally, Mike Hennesy, Vice President of Innovation shared the following about how it works. Naturally hemp-derived sleep gummies contain the same cannabinoids like CBD, CBN, and THC as cannabis or marijuana. These ingredients interact with receptors in the body’s endocannabinoid system, which plays a role in regulating mood, stress, and sleep-wake cycles. For example, CBD may promote relaxation and reduce anxiety, CBN can relieve discomfort and reduce awakenings, while THC can shorten the time it takes to fall asleep, especially at low doses. Together, they may help ease the mind and body into a sleep-ready state.
The best sleep products don’t rely on just one cannabinoid like CBN but instead use a combination of cannabinoids, terpenes, and other sleep-supporting ingredients such as melatonin. This is because the reasons for sleeplessness are multifaceted, and include trouble falling asleep, staying asleep, chronic, pain and anxiety. Each ingredient targets different root causes as well as synergizes with the other cannabinoids and terpenes for the best night sleep.
Longer lasting formulations can actually help reduce awakenings in the night. CBN has been shown in recent research to reduce the number of times you wake up in the night. Combined with other cannabinoids they can synergize to reduce discomfort and anxiety helping consumers stay asleep.
If you do wake up in the middle of the night and can’t fall back asleep products including CBD and CBG to reduce middle of the night anxiety and racing thoughts that can keep us awake, and they have only 1mg of THC so you wake up refreshed and not high in the morning.
For most people, hemp-derived cannabinoids are considered safe and non-intoxicating, with a low risk of dependence. When THC is included in small amounts, it can produce mild effects and can help us fall asleep faster. It generally poses a minimal risk when used in moderation, but there is a potential for dependence if overused, just like with any sleep aid. Adverse events are far more prevalent in pharmaceutical and even over the counter sleep aids than with hemp-derived cannabinoids.
The key is responsible use, including starting with a low dose and taking breaks when needed. If you rely on it every night at high doses, your body may adjust, and it can be habitual. But when used in moderation and with a well-balanced formula, cannabis can be a sustainable part of a healthy sleep routine.
Alcohol has some negative side effects, but cannabis could have one positive health benefit – it might help your good cholesterol.
In the late 1980s cholesterol test became come as the impact of it on the body and heart was becoming more evident. Research shows good cholesterol (HDL) helps remove excess cholesterol from the body, while “bad” cholesterol (LDL) can build up in arteries, potentially leading to heart disease. Alcohol and tobacco are known to be rough on the body, but can marijuana help cholesterol?
Marijuana’s potential impact on cholesterol is an emerging area of research, offering both promising insights and areas for further exploration. While studies have yet to reach definitive conclusions, evidence suggests that cannabis may influence cholesterol levels in ways that could benefit cardiovascular health under certain conditions.
Cannabis contains cannabinoids like THC and CBD, which interact with the body’s endocannabinoid system. This system plays a role in regulating various physiological processes, including lipid metabolism. Some studies have indicated that marijuana use might improve cholesterol profiles by increasing high-density lipoprotein (HDL), commonly known as “good cholesterol.” For instance, research published in BMJ Open found that marijuana users had elevated levels of HDL cholesterol, which is associated with better cardiovascular health.
Moreover, cannabis has demonstrated anti-inflammatory properties and the ability to regulate blood glucose levels. These effects can indirectly support heart health by reducing risk factors associated with high cholesterol, such as diabetes and obesity. Additionally, cannabinoids like CBD may help protect the heart from oxidative stress and inflammation, further enhancing cardiovascular health.
Cannabis has also been linked to weight management benefits, which can positively impact cholesterol levels. Studies have shown that marijuana use may reduce abdominal fat and improve metabolic parameters. Since obesity is a major contributor to high LDL cholesterol levels, these findings suggest that cannabis could play a supportive role in maintaining healthy cholesterol levels.
While some studies highlight potential benefits of cannabis for cholesterol and heart health, others caution against its risks. Daily marijuana use has been associated with an increased risk of heart failure and other cardiovascular issues. However, research also indicates that cannabis may reduce the risk of atrial fibrillation and improve outcomes following heart attacks.